Modality
Gene Editing
MOA
Anti-Tau
Target
KRASG12C
Pathway
RAS/MAPK
RAMDD
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
Oct 2020
→ May 2025
Phase 2Current
NCT03034631
995 pts·RA
2025-11→TBD·Recruiting
NCT06515982
1,511 pts·MDD
2020-10→2025-05·Active
2,506 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-0111mo agoPh3 Readout· MDD
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2/3
Active
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-05-01 · 11mo ago
MDD
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03034631 | Phase 2/3 | RA | Recruiting | 995 | OS |
| NCT06515982 | Phase 2/3 | MDD | Active | 1511 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C |